NCT07227506 Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:
| NCT ID | NCT07227506 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical College of Wisconsin |
| Condition | Gerd |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-11-20 |
| Primary Completion | 2027-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2025-11-20 with a primary completion date of 2027-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background \& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis are common gastrointestinal disorders affecting nearly 20% and 0.1% of the population, respectively. Although these conditions are frequent, the diagnosis of GERD or EoE requires complex decision making involving endoscopic examination, histopathological examination, and esophageal pH testing. This translates into significant economic burden; For example, burden due to GERD is about $24 billion annually. Additionally, there may be a delay in the diagnosis of GERD or EoE as Investigators might have to do multiple procedures such as upper endoscopy, esophageal pH testing, etc for the same participant for confirmation of the diagnosis. In addition, there could be overlay between GERD and EoE in the diagnosis which make cause delay in the diagnosis and decision making. Aim: Here, Investigators will plan to identify the diagnostic utility and cost-effectiveness of this novel Mivu device(FDA approved) in the diagnosis of gastroesophageal reflux disease or chronic esophageal inflammatory disorders in participants with reflux symptoms or chronic esophageal symptoms.
Eligibility Criteria
Inclusion Criteria: 1\. Patients with chronic esophageal symptoms such as atypical or typical reflux symptoms and dysphagia, is here for upper endoscopy testing. Exclusion Criteria: 1. Presence of esophageal stricture 2. Unstable patients who cannot undergo this testing. 3. Patients on anticoagulation on the day of procedure. 4. Presence of esophageal cancer. 5. Pregnancy. 6. Minor patients.
Frequently Asked Questions
Who can join the NCT07227506 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Gerd. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07227506 currently recruiting?
Yes, NCT07227506 is actively recruiting participants. Visit ClinicalTrials.gov or contact Medical College of Wisconsin to inquire about joining.
Where is the NCT07227506 trial being conducted?
This trial is being conducted at Milwaukee, United States.
Who is sponsoring the NCT07227506 clinical trial?
NCT07227506 is sponsored by Medical College of Wisconsin. The trial plans to enroll 50 participants.